Rashid Kamran, Ng Richard, Mastan Alina, Sager Dianne, Hirschman Richard
Division of Hematology-Oncology, Cabrini Medical Center, NY 10003, USA.
Leuk Lymphoma. 2005 Jul;46(7):1051-5. doi: 10.1080/10428190500096989.
We present four patients with chronic lymphocytic leukemia treated with fludarabine, who developed aggressive skin cancer after years of quiescence, a short time after institution of treatment. Their leukemias responded well to therapy with fludarabine with initial treatment as well as relapse. Three patients had recurrence with basal cell carcinomas with multiple, rapidly growing tumors and one had recurrence of both basal and squamous cancers and eventually died of metastatic squamous cell carcinoma. Fludarabine induces prolonged period of lymphopenia, affecting especially the T cell population, which is crucial in the defense against skin cancers. There appears to be a direct association between fludarabine and the flare up of skin cancers in these patients, possibly analogous to the increased incidence of these malignancies in patients on chronic cyclosporine immunosuppression.
我们报告了4例接受氟达拉滨治疗的慢性淋巴细胞白血病患者,他们在病情静止多年后,于开始治疗后不久发生了侵袭性皮肤癌。他们的白血病对氟达拉滨初始治疗及复发后的治疗反应良好。3例患者复发为基底细胞癌,有多个快速生长的肿瘤,1例患者基底癌和鳞状细胞癌均复发,最终死于转移性鳞状细胞癌。氟达拉滨可导致淋巴细胞减少期延长,尤其影响T细胞群体,而T细胞群体在抵御皮肤癌方面至关重要。在这些患者中,氟达拉滨与皮肤癌的突然发作之间似乎存在直接关联,这可能类似于接受慢性环孢素免疫抑制治疗的患者中这些恶性肿瘤发病率的增加。